Temferon is under clinical development by Genenta Science and currently in Phase II for Supratentorial Glioma. According to GlobalData, Phase II drugs for Supratentorial Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Temferon LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Temferon overview

Temferon is under development for the treatment of glioblastoma multiforme, supratentorial glioblastoma, hepatocellular carcinoma, renal cell cancer and metastatic renal cell carcinoma, intra-hepatic cholangiocarcinoma, solid tumors and hematological malignancies, breast cancer, melanoma, colorectal cancer (CRC), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), metastatic urothelial carcinoma (mUC) and bladder cancer. It is administered through parenteral route. The therapeutic candidate consists of engineered autologous hematopoietic stem cells which are transduced with TIE2-IFN-mirT lentiviral vector. It acts by targeting interferon-alpha (IFN alpha) transgene under the control of the Tie2 promoter.

It was also under development for the treatment of relapsed multi myeloma.

Genenta Science overview

Genenta Science, formerly Genenta Science, is a biotechnology company that discovers and develops cell and gene therapies for cancer. It investigates Temferon, a lenti-virus based hematopoietic stem progenitor cell immuno therapy for the treatment of glioblastoma multiforme, solid and hematologic tumors. Its drug candidate enables controlled and targeted interferon-a expression within cancers. Genenta Science utilizes its proprietary TEMs (Tie2 expressing monocytes) platform that centers on a transgene expression control vector providing dual control at the transcriptional and post-transcriptional level. The company is a spin-out from the San Raffaele Hospital. Geneta Science is headquartered in Milan, Lombardy, Italy.

For a complete picture of Temferon’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.